NCT04980014View on ClinicalTrials.gov

A Post-Marketing Surveillance Study on NesinaAct® Tablet Use Among Type 2 Diabetes Mellitus Participants in Korea

CompletedOBSERVATIONAL
Enrollment

730

Participants

Timeline

Start Date

October 2, 2015

Primary Completion Date

August 30, 2019

Study Completion Date

August 30, 2019

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

NesinaAct® Tablet

NesinaAct® tablet is a fixed dose combination (FDC) of alogliptin benzoate with pioglitazone HCl.

Trial Locations (8)

Unknown

Busan

Chuncheon

Daejeon

Gangneung-si

Goyang-si

Jeonju

Seongam

Seoul

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY